To determine the effectiveness of dasatinib for treating c-Cbl-associated MPD we established a cohort of c-CblA/− mice aged 8–9 months that was dosed once daily for 4 weeks with 15 mg/kg of dasatinib or vehicle. The gene discussed is CBL; the disease is myeloproliferative disorder.